RTP Mobile Logo
AcuteLeukemiasUpdate119

Interview with Mark Levis, MD, PhD

 

Track 1: Molecular profiling in the diagnosis and treatment of acute myeloid leukemia (AML)
Track 2: Management of AML with p53 mutations
Track 3: Efficacy of hypomethylating agents with venetoclax in older patients with AML
Track 4: Therapeutic options for patients with AML and FLT3 mutations
Track 5: Monitoring and management of venetoclax-associated tumor lysis syndrome
Track 6: Case: A 62-year-old woman who presents with fatigue and bleeding gums is diagnosed with AML with FLT3 and NPM1 mutations
Track 7: Role of the FLT3 pathway in myeloid cell development and types of FLT3 mutations
Track 8: Impact of FLT3 mutations on therapeutic decision-making
Track 9: Activity of midostaurin in newly diagnosed AML with a FLT3 mutation
Track 10: BMT CTN 1506: A Phase III trial of gilteritinib as maintenance therapy after allogeneic transplant for patients with AML and FLT3-ITD mutations
Track 11: Case: A 60-year-old man with AML and a FLT3-ITD mutation receives gilteritinib with standard 7 + 3 chemotherapy induction followed by allotransplant and maintenance gilteritinib on a clinical trial
Track 12: Similarities and differences among midostaurin, quizartinib and gilteritinib
Track 13: Case: A 63-year-old man with refractory AML and an IDH2 mutation receives enasidenib and develops differentiation syndrome
Track 14: Biologic rationale for targeting IDH1/2 mutations and activity of ivosidenib or enasidenib in patients with relapsed/refractory AML
Track 15: Efficacy and side effects of CPX-351 (liposomal cytarabine/daunorubicin) in patients with AML
Track 16: Case: A 28-year-old obese man with acute lymphoblastic leukemia (ALL) and an MLL rearrangement develops hepatic toxicity after treatment with the Berlin-Frankfurt-Munster pediatric-inspired regimen containing L-asparaginase
Track 17: Mechanism of action, activity and tolerability of blinatumomab for ALL
Track 18: Neurologic side effects associated with blinatumomab
Track 19: Use of blinatumomab for minimal residual disease-positive ALL
Track 20: Optimal use of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive ALL
Track 21: Case: A 41-year-old woman receives chimeric antigen receptor (CAR) T-cell therapy for relapsed ALL
Track 22: Role of CAR T-cell therapy in the management of ALL
Track 23: Use of the antibody-drug conjugates gemtuzumab ozogamicin and inotuzumab ozogamicin for acute leukemias
Track 24: Activity of gemtuzumab ozogamicin in patients with high-risk acute promyelocytic leukemia (APL)

Interview with Farhad Ravandi, MD

Track 1: Impact of genetic mutations and cytogenetic alterations on prognosis and therapy selection for patients with AML
Track 2: Initial workup for patients with newly diagnosed AML
Track 3: Biologic rationale for, activity of and approval of venetoclax in combination with hypomethylating agents for patients with AML who are 75 or older or have comorbidities
Track 4: Integration of venetoclax with hypomethylating agents into the clinical algorithm for AML
Track 5: Approach to therapy for older patients with AML and FLT3 mutations
Track 6: Management of toxicities associated with venetoclax combined with a hypomethylating agent
Track 7: RATIFY: Results of a Phase III trial evaluating midostaurin with 7 + 3 induction and high-dose cytarabine consolidation and as maintenance therapy for patients with newly diagnosed AML and FLT3 mutations
Track 8: Efficacy of sorafenib, quizartinib or gilteritinib for patients with AML and FLT3 mutations
Track 9: Side effects and spectrum of activity of gilteritinib, quizartinib and midostaurin
Track 10: Case: A 70-year-old man with AML and NPM1 and FLT3 mutations receives azacitidine in combination with venetoclax and sorafenib as third-line therapy
Track 11: Case: A 44-year-old woman with AML and an IDH2 mutation receives enasidenib
Track 12: Perspective on the potential use of enasidenib or ivosidenib in the first-line setting
Track 13: Mechanism of action and efficacy of CPX-351 in patients with therapy-related AML or AML with myelodysplasia-related changes
Track 14: Clinical experience with CPX-351
Track 15: Role of gemtuzumab ozogamicin in the treatment of CD33-positive AML
Track 16: Activity of the recently approved hedgehog inhibitor glasdegib in combination with low-dose cytarabine for newly diagnosed AML in patients aged 75 or older or those with comorbidities
Track 17: Case: A 75-year-old woman with AML and significant comorbidities is enrolled on a clinical trial of decitabine with venetoclax
Track 18: Case: A 76-year-old woman with ALL experiences a complete remission with blinatumomab as second-line therapy
Track 19: Mechanism of action and efficacy of blinatumomab for ALL
Track 20: Activity and tolerability of CAR T-cell therapy for ALL
Track 21: Cytokine release syndrome and neurologic toxicities associated with CAR T-cell therapy and blinatumomab
Track 22: Perspective on the role of tyrosine kinase inhibitors in the treatment of Philadelphia chromosome-positive ALL
Track 23: Efficacy of gemtuzumab ozogamicin in patients with high-risk APL
 
FACULTY
 
Mark Levis, MD, PhD
Director, Adult Leukemia Program
Co-Division Director, Hematologic Malignancies
Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland
 
Farhad Ravandi, MD
Janiece and Stephen A Lasher
Professor of Medicine
Chief, Section of Developmental Therapeutics
Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, Texas
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida